Dallah Healthcare Company Stock

Equities

4004

SA135G51UI10

Healthcare Facilities & Services

Market Closed - Saudi Arabian S.E. 08:20:03 2024-06-06 am EDT 5-day change 1st Jan Change
164.4 SAR +0.74% Intraday chart for Dallah Healthcare Company -0.36% -4.31%
Sales 2024 * 3.3B 880M Sales 2025 * 3.55B 947M Capitalization 15.94B 4.25B
Net income 2024 * 436M 116M Net income 2025 * 514M 137M EV / Sales 2024 * 5.35 x
Net Debt 2024 * 1.7B 455M Net Debt 2025 * 1.68B 447M EV / Sales 2025 * 4.96 x
P/E ratio 2024 *
37.1 x
P/E ratio 2025 *
30.8 x
Employees -
Yield 2024 *
1.45%
Yield 2025 *
1.84%
Free-Float 41.94%
More Fundamentals * Assessed data
Dynamic Chart
Dallah Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Dallah Healthcare Posts Higher Q1 Net Profit, Revenue MT
Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dallah Healthcare Logs Higher FY23 Net Profit, Revenue MT
Ayyan Investment Appoints Financial Adviser for Share Exchange Deal with Dallah Healthcare MT
Dallah Healthcare Company signed of a non-binding memorandum agreement to acquire 97% stake in Al-Ahsa Medical Services Company and 100% stake in Al-Salam Medical Services Company from Ayyan Investment Company. CI
Dallah Healthcare Co. Announces the Distribution of Cash Dividends for the Fourth Quarter of 2023, Payable on 30 January 2024 CI
Dallah Healthcare Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Dallah Healthcare Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Dallah Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Dallah Healthcare Company completed the acquisition of an additional 18.98% stake in International Medical Centre. CI
Dallah Healthcare Co. Announces the Distribution of Cash Dividends for Second Half of the Fiscal Year 2022, Payable on December 29, 2022 CI
Dallah Healthcare Company Approves Resignation of Fahad Bin Abdulaziz Al-Rabiah as Board of Directors and Compensation and Remuneration Committee CI
Dallah Healthcare Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
1 day-0.74%
1 week-1.82%
Current month-1.82%
1 month+0.75%
3 months-10.69%
6 months-4.71%
Current year-5.70%
More quotes
1 week
161.40
Extreme 161.4
168.80
1 month
158.00
Extreme 158
170.00
Current year
158.00
Extreme 158
194.00
1 year
131.40
Extreme 131.4
194.00
3 years
65.00
Extreme 65
194.00
5 years
34.75
Extreme 34.75
194.00
10 years
32.45
Extreme 32.4497
194.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 08-03-28
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member - -
Chairman 67 93-12-31
Director/Board Member 43 16-10-20
More insiders
Date Price Change Volume
24-06-06 164.4 +0.74% 65 967
24-06-05 163.2 -1.57% 81,429
24-06-04 165.8 -0.36% 78,582
24-06-03 166.4 +0.36% 107,359
24-06-02 165.8 +0.48% 91,676

Delayed Quote Saudi Arabian S.E., June 06, 2024 at 03:47 am EDT

More quotes
Dallah Healthcare Company SJSC, formerly Dallah Healthcare Co, is a Saudi Arabia-based company engaged in the provision and operation of healthcare programs and utilities. The Company operates in the following business segments: Hospitals; Medicines, and Head Office. The Hospitals’ segment objectives are to own, manage, operate and maintain healthcare facilities. The Medicines’ segment objectives are to import, distribute, wholesale and retail medicines, as well as manufacture medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging materials. The Head Office’s segment objectives are to operate, manage and maintain healthcare facilities; wholesale and retail surgical equipment, artificial parts, handicapped and hospitals equipment, as well as other supporting services.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
10
Last Close Price
163.2 SAR
Average target price
155.2 SAR
Spread / Average Target
-4.91%
Consensus